Eighty-five new patients in a single quarter is a thin number for a commercial launch — but in relapsed/refractory NPM1-mutant AML, a disease affecting roughly 30% of AML cases and historically served by a bare handful of approved agents, 85 starts with a repeat-prescription rate implying nearly two scripts per patient tells a more pointed story than the headline revenue figure suggests. Kura’s $5.8 million in first-quarter net product revenue for ziftomenib lands below what a blockbuster launch looks like, but the unit economics are not the real strategic bet here.
The actual wager Kura is making is combinability. Every active trial — KOMET-007 pairing ziftomenib with 7+3 induction, KOMET-008 stacking it with gilteritinib in FLT3/NPM1 co-mutated patients, the venetoclax-plus-azacitidine arm with data expected in the first half of this year — is designed to make ziftomenib indispensable to the regimen rather than competitive with it. That framing matters enormously for payer negotiations and for insulating market share against Syndax’s revumenib, the only other approved menin inhibitor. Physicians already switching to ziftomenib from a rival compound in a market with exactly one competitor signals something real about clinical preference, though the absolute numbers remain small enough that a single safety signal or combination trial disappointment would reverse that momentum fast.
The burn rate deserves direct attention. Cash dropped from $667 million at year-end 2025 to $581 million by March 31 — an $86 million quarterly drawdown against $18 million in total revenue. R&D spending rose 17% year-over-year to $65 million, driven by KOMET-017, the Phase 3 frontline program that is the true valuation fulcrum. SG&A at $31.6 million for a drug generating $5.8 million in product revenue is a ratio that only makes sense if you believe the combination data arriving this year dramatically expands the addressable population beyond second-line NPM1-mutant disease. The $180 million in anticipated collaboration payments provides a meaningful buffer, but Kura is explicitly underwriting this spend against KOMET-017’s first topline read.
The single variable that determines whether this commercial infrastructure investment is vindicated or ruinous is the KOMET-007 oral presentation at EHA in June — frontline combination data in NPM1-mutant and KMT2A-rearranged AML will either validate ziftomenib’s backbone ambitions or expose them as premature.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
